BMI1 is useful as a biomarker for predicting malignant myeloid progression in a subset of either MDS or CML-CP by epigenetically reprogramming the H3 acetylation profile which also may contribute to the poor prognosis of these diseases. The gene discussed is BMI1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.